The ODAC will weigh risk-benefit analyses from the FDA and sponsors on Keytruda, Opdivo, and Tevimbra when given with chemo in all comers and in PD-L1-positive subgroups.
The Senate Homeland Security and Governmental Affairs Committee issued a 134-page report that details the operations and communication failures that allowed a 20-year-old gunman to climb atop an ...